BMPR2 and pulmonary arterial hypertension: Compared to lung 18FLT uptake in control subjects, the mean 18FLT phosphorylation k3 was not significantly different in PAH patients (Fig. 1a), so as in the unaffected BMPR2 mutation carriers.